Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Moxifloxacin-induced acute liver injury.

Literature DB >> 12135060

Moxifloxacin-induced acute liver injury.

Santiago Soto, Leopoldo López-Rosés, Susana Avila, Angel Lancho, Abel González, Eva Santos, Begoña Urraca.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2002 PMID： 12135060 DOI： 10.1111/j.1572-0241.2002.05873.x

Source DB: PubMed Journal: Am J Gastroenterol ISSN： 0002-9270 Impact factor: 10.864

Keyword Cloud
Cited

× No keyword cloud information.

13 in total

1. Clinical and histopathologic features of fluoroquinolone-induced liver injury.

Authors: Eric S Orman; Hari S Conjeevaram; Raj Vuppalanchi; James W Freston; James Rochon; David E Kleiner; Paul H Hayashi
Journal: Clin Gastroenterol Hepatol Date: 2011-02-26 Impact factor: 11.382

Review 2. Hepatotoxic effects of therapies for tuberculosis.

Authors: Bahaa E Senousy; Sanaa I Belal; Peter V Draganov
Journal: Nat Rev Gastroenterol Hepatol Date: 2010-08-31 Impact factor: 46.802

3. Effect of PEG and water-soluble chitosan coating on moxifloxacin-loaded PLGA long-circulating nanoparticles.

Authors: Sanaul Mustafa; V Kusum Devi; Roopa S Pai
Journal: Drug Deliv Transl Res Date: 2017-02 Impact factor: 4.617

4. Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.

Authors: Kelly Dooley; Charles Flexner; Judith Hackman; Charles A Peloquin; Eric Nuermberger; Richard E Chaisson; Susan E Dorman
Journal: Antimicrob Agents Chemother Date: 2008-09-02 Impact factor: 5.191

Review 5. Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes.

Authors: Françoise Van Bambeke; Paul M Tulkens
Journal: Drug Saf Date: 2009 Impact factor: 5.606

Moxifloxacin-induced acute liver injury.

1. Clinical and histopathologic features of fluoroquinolone-induced liver injury.

Review 2. Hepatotoxic effects of therapies for tuberculosis.

3. Effect of PEG and water-soluble chitosan coating on moxifloxacin-loaded PLGA long-circulating nanoparticles.

4. Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.

Review 5. Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes.

Review 6. Fluoroquinolone-induced liver injury: three new cases and a review of the literature.

Review 7. Hepatic safety of antibiotics used in primary care.

8. Incidence, clinical features, and risk factors of fluoroquinolone-induced acute liver injury: a case-control study.

9. Moxifloxacin induced fatal hepatotoxicity in a 72-year-old man: a case report.

Review 10. A brief review of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia (CAP).